stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
49.25
4.46
+9.96%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Operating cash flow
Enliven Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$70.3M, compared with −$73.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$66.9M. Over the past ten years it has ranged from −$73.2M (fiscal 2024) to −$8.8M (fiscal 2018); the current reading is higher than 22% of that period. Enliven Therapeutics, Inc. ranks 391st of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$70.3M | — |
| FY2024 | −$73.2M | — |
| FY2023 | −$61.3M | — |
| FY2022 | −$32.1M | — |
| FY2021 | −$46.8M | — |
| FY2020 | −$37.4M | — |
| FY2019 | −$21.9M | — |
| FY2018 | −$8.8M | — |
| FY2017 | −$8.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$18.5M | — |
| Mar 2026 | −$19.3M | — |
| Dec 2025 | −$15.8M | — |
| Sep 2025 | −$13.3M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$73.2M
High −$8.8M
Ten-year median
−$37.4M
Current reading's percentile
22
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| TLX Telix Pharmaceuticals Limited compare | $51.9M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. | −$66.9M |
| CELC Celcuity, Inc. compare | −$191.7M |
| VRDN Viridian Therapeutics, Inc. compare | −$341.5M |
| DNLI Denali Therapeutics Inc. compare | −$444.2M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item